Glycopeptide pharmacokinetics in current paediatric cardiac surgery practice
- PMID: 17689968
- DOI: 10.1016/j.ejcts.2007.07.008
Glycopeptide pharmacokinetics in current paediatric cardiac surgery practice
Abstract
Objective: To examine the evolution of serum concentrations of prophylactic glycopeptides administered during state-of-the-art cardiopulmonary bypass (CPB) and vigorous haemodiafiltration in paediatric patients undergoing cardiac surgery.
Methods: We enrolled infants and children <3 years of age who, based on the preoperative microbiological screening, age and surgical complexity, were at high risk of methicillin-resistant Staphylococcus aureus (MRSA) infection. Antimicrobial prophylaxis with glycopeptides was administered to 22 patients, randomly assigned to vancomycin (VAN; n=11) versus teicoplanin (TEC; n=11). Fixed doses of each drug (15 mg/kg for VAN and 8 mg/kg for TEC) were administered immediately before the operation, at the time of priming of the extracorporeal circuit, upon admission to the intensive care unit and for 48 h thereafter, q. 8 h for VAN, and once daily for TEC. Vigorous haemodiafiltration was applied during and briefly after CPB.
Results: The second dose of drug added to the prime prevented a fall in serum drug concentrations at the onset of CPB in both groups. A 77% decrease in VAN, versus 53% in TEC concentrations, was observed after the conclusion of CPB. Serum concentrations of TEC>10 microg/ml were observed throughout the treatment period in 91% of patients, while 55% of patients assigned to VAN had serum concentrations consistently >5 microg/ml (p=0.08). Therapeutic serum concentrations were maintained throughout the intraoperative period, particularly with TEC, administered before the first surgical incision, followed by a supplemental bolus in the priming fluid of CPB. Postoperative surgical wound infections occurred in neither group.
Conclusions: The prophylactic use of glycopeptides in paediatric patients at high risk of MRSA infection undergoing cardiac surgery was safe and effective. TEC might be the drug of choice, since stable, therapeutic serum concentrations were easily maintained throughout the treatment period.
Similar articles
-
Effects of controlled perioperative antimicrobial prophylaxis on infectious outcomes in pediatric cardiac surgery.Crit Care Med. 2007 Jul;35(7):1763-8. doi: 10.1097/01.CCM.0000269027.50834.FE. Crit Care Med. 2007. PMID: 17507823 Clinical Trial.
-
Treatment of infective endocarditis caused by methicillin-resistant Staphylococcus aureus: teicoplanin versus vancomycin in a retrospective study.Scand J Infect Dis. 2008;40(6-7):462-7. doi: 10.1080/00365540701837126. Scand J Infect Dis. 2008. PMID: 18584532
-
Vancomycin versus teicoplanin in the therapy of experimental methicillin-resistant Staphylococcus aureus (MRSA) meningitis.Int J Antimicrob Agents. 2005 Nov;26(5):412-5. doi: 10.1016/j.ijantimicag.2005.08.011. Epub 2005 Oct 10. Int J Antimicrob Agents. 2005. PMID: 16221540
-
Key considerations in the treatment of complicated staphylococcal infections.Clin Microbiol Infect. 2008 Mar;14 Suppl 2:3-9. doi: 10.1111/j.1469-0691.2008.01923.x. Clin Microbiol Infect. 2008. PMID: 18226084 Review.
-
[New therapeutic strategies with teicoplanin].Medicina (B Aires). 2002;62 Suppl 2:25-9. Medicina (B Aires). 2002. PMID: 12481485 Review. Spanish.
Cited by
-
Silica-Coated Magnetic Nanoparticles for Vancomycin Conjugation.ACS Omega. 2022 Aug 16;7(34):30161-30170. doi: 10.1021/acsomega.2c03226. eCollection 2022 Aug 30. ACS Omega. 2022. PMID: 36061717 Free PMC article.
-
Antibiotic prophylaxis for the prevention of methicillin-resistant Staphylococcus aureus (MRSA) related complications in surgical patients.Cochrane Database Syst Rev. 2013 Aug 19;2013(8):CD010268. doi: 10.1002/14651858.CD010268.pub2. Cochrane Database Syst Rev. 2013. PMID: 23959704 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical